EUVIMEDEUVIMED entdecken
Multizentrische Studie

A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion

Ze Song, De-Di Wu, Wen-Zhe Fan, Min-Jiang Wu, Hong-Fei Miao, Jia-Hang Du, Hao Zhang, Dai-Rong Jiang, Ying-Qiang Zhang iD

Abdominal Radiology · 2024

DOI: 10.1007/s00261-024-04490-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Abdominal Radiology, 2024. Verfasst von Ze Song und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Portal Vein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although systemic therapies are recommended for hepatocellular carcinoma (HCC) patients with main portal vein (MPV) invasion and preserved liver function, the outcome is limited. In the real-world, chemoembolization is a commonly used local treatment for advanced HCC. PURPOSE: To evaluate whether the additional chemoembolization treatment yields survival benefits compared to systemic therapy for HCC patients with MPV invasion and preserved liver function (Child-Pugh score ≤ B7) in a real-world study from multiple centers. PATIENTS AND METHODS: Between January 2020 and December 2022, 91 consecutive HCC patients with MPV invasion who received either systemic medical therapy (i.e., tyrosine kinase inhibitors (TKIs) plus anti-PD-1 immunotherapy, S group, n = 43) or in combination with chemoembolization treatment (S-T group, n = 48) from five centers were enrolled in the study. The primary outcome was overall survival (OS), and the secondary outcomes were progression-free survival (PFS) and treatment response. Adverse events (AEs) related to treatment were also recorded. Survival curves were constructed with the Kaplan-Meier method and compared using the log-rank test. RESULTS: The baseline characteristics were comparable between the two groups. The mean number of chemoembolization sessions per patient was 2.1 (range 1-3). The median OS was 10.0 months and 8.0 months in the S-T group and S group, respectively (P = 0.254). The median PFS between the two groups was similar (4.0 months vs. 4.0 months, P = 0.404). The disease control rate between the S-T and S groups were comparable (60.4% vs. 62.8%, P = 0.816). Although no chemoembolization-related deaths occurred, 13 grade 3-4 AEs occurred in the S-T group. CONCLUSIONS: The results of the real-world study demonstrated that additional chemoembolization treatment did not yield survival benefits compared to TKIs plus anti-PD-1 immunotherapy for the overall patients with advanced HCC and MPV invasion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticPortal VeinProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesNeoplasm InvasivenessCombined Modality TherapyAdultImmune Checkpoint InhibitorsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ChemoembolizationHepatocellular carcinomaSurvivalSystemic therapyThrombosis

Substanzen

Protein Kinase InhibitorsImmune Checkpoint InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
  • Department of Interventional Radiology, The Seventh Affiliated Hospital, Sun Yat-Sen University, 628 Zhenyuan Road, Shenzhen, 518107, China.
  • Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Pharmacy, Huizhou Municipal Centre Hospital, Office of GCP, Huizhou, China.
  • Division of Vascular and Interventional Radiology, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Ultrasonography, Hunan Provincial Maternal and Child Health Care Hospital, No. 53 Xiangchun Road, Changsha, 410008, China. dairongj28@163.com.

ORCID-Profile: Ying-Qiang Zhang

Zitieren

APA

Song, Z., Wu, D. D., Fan, W. Z., Wu, M. J., Miao, H. F., Du, J. H., Zhang, H., Jiang, D. R., & Zhang, Y. Q. (2024). A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion. Abdominal Radiology. https://doi.org/10.1007/s00261-024-04490-7

Vancouver

Song Z, Wu DD, Fan WZ, Wu MJ, Miao HF, Du JH, et al. A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion. Abdominal Radiology. 2024. doi:10.1007/s00261-024-04490-7

BibTeX
@article{Song2024,
  author = {Song, Ze and Wu, De-Di and Fan, Wen-Zhe and Wu, Min-Jiang and Miao, Hong-Fei and Du, Jia-Hang and Zhang, Hao and Jiang, Dai-Rong and Zhang, Ying-Qiang},
  title = {A real-world study of tyrosine kinase inhibitors plus anti-PD-1 immunotherapy with or without chemoembolization for hepatocellular carcinoma patients with main portal vein invasion},
  journal = {Abdominal Radiology},
  year = {2024},
  doi = {10.1007/s00261-024-04490-7}
}
Kostenlos starten →